Moderna’s Bob Langer and Yann LeCun Join Cellular Intelligence Board
Cellular Intelligence announced the addition of Bob Langer and Yann LeCun to its advisory board, pairing deep‑learning expertise with decades of drug‑development experience. The company aims to use AI to predict cell behavior, accelerating therapies such as a Parkinson’s disease cell therapy. The m…
By Felo News Desk · Published
Cellular Intelligence, a Boston‑based startup founded in 2023, has added two high‑profile figures to its scientific advisory board: Moderna co‑founder Robert “Bob” Langer and Turing Award‑winning AI researcher Yann LeCun. The appointment also includes Jens Nielsen, chief executive of the Novo Nordisk Foundation’s BioInnovation Institute, and Fabian Theis, computational biologist and director of the Computational Health Center at Helmholtz Munich. Langer will serve as an observer on the company’s board of directors.
Bridging Biology and Artificial Intelligence
For decades, developing new medicines—especially cell therapies that use living cells instead of chemical compounds—has been a slow, expensive, trial‑and‑error process. Cellular Intelligence (CI) seeks to change that by applying the pattern‑recognition techniques that power modern AI systems to biology. The company’s goal is to train a model on vast amounts of cellular data so it can predict how cells will respond to different signals, potentially eliminating the need for laborious wet‑lab testing.
By pairing Langer, a medical researcher with no AI background, with LeCun, an AI researcher with no biology background, CI demonstrates that it has genuine expertise on both sides of the equation. “What matters to me is whether the science can lead to something that makes a difference for patients, and whether the people involved can carry it through,” Langer told Fortune. “I have been doing this for over 50 years, and [CI’s CEO] Micha and the scientific team he has brought together are among the very best I have seen.”
Key Expertise on the Board
- Yann LeCun – 2018 ACM A.M.Turing Award winner, former chief AI scientist at Meta, and current executive chairman of AMI Labs, which focuses on world‑model AI.
- Bob Langer – MIT Institute Professor, holder of more than 1,500 patents, co‑founder of roughly 40 companies, and recipient of the National Medal of Science.
- Jens Nielsen – CEO of the BioInnovation Institute, a Novo Nordisk Foundation‑backed life‑science incubator based in Copenhagen.
- Fabian Theis – Director of the Computational Health Center at Helmholtz Munich, co‑founder of the Human Cell Atlas, and 2023 Leibniz Prize winner for machine‑learning methods.
Accelerating Parkinson’s Therapy
CI’s board expansion follows the company’s May acquisition of global rights to STEM‑PD, an experimental Parkinson’s disease cell therapy originally developed by Novo Nordisk. The therapy, designed to replace dopamine‑producing neurons lost to Parkinson’s, has received FDA Fast Track designation and is ready for Phase 2 trials. Novo Nordisk took an equity stake in CI as part of the deal and remains eligible for future milestones and royalties.
“Novo Nordisk selected CI to advance STEM‑PD, and we acquired global rights to a Phase 2‑ready Parkinson’s program with FDA IND clearance and Fast Track designation,” CEO Micha Breakstone said. “Novo also made a strategic equity investment in CI. We see that as a strong vote of confidence in the next chapter of this work.”
Future Plans and Funding
CI plans to license its AI models to pharmaceutical partners for paid drug‑discovery work while also developing additional medicines in-house or through collaborations. The company has raised more than $70 million from investors such as Khosla Ventures, the Chan Zuckerberg Initiative, and Novo Nordisk. Langer’s involvement comes alongside his support of other biotech ventures, including Vivtex’s $2.1 billion deal with Novo Nordisk and his children’s startups Soufflé Therapeutics and T. Rx Capital.
With its proprietary engine for generating biological data, a foundation model trained on that data, and an owned clinical program, CI is poised to test the practical value of its predictions. Early internal benchmarks show stronger prediction results than existing models in both healthy development and cancer, even though the models have never been trained on a single cancer cell.
As the company moves forward, the collaboration between deep‑learning experts and seasoned biopharma leaders could signal a new era in drug discovery—one where AI not only predicts outcomes but also guides the design of living therapeutics.
Key facts
- CI adds Bob Langer and Yann LeCun to its advisory board
- The company focuses on AI models that predict cell behavior
- Acquisition of STEM‑PD gives CI a Phase 2‑ready Parkinson’s therapy
- Novo Nordisk invested equity and retains future milestone rights
- CI aims to license AI models and develop additional medicines
Why it matters
By uniting top AI talent with seasoned drug‑development experts, Cellular Intelligence could dramatically shorten the time and cost of bringing new cell‑based therapies to patients, potentially transforming treatment for diseases like Parkinson’s.
Frequently asked questions
What is Cellular Intelligence’s main goal?
To build AI models that predict and control how living cells behave, accelerating drug discovery.
What does the new board bring to the company?
A mix of deep‑learning expertise from LeCun and drug‑development experience from Langer, plus support from Nielsen and Theis.
What is STEM‑PD?
An experimental Parkinson’s disease cell therapy that replaces lost dopamine‑producing neurons, now Phase 2‑ready.
Sources
- [1] fortune.com — originally reported as “Moderna's Bob Langer and AI pioneer Yann LeCun join board of Cellular Intelligence, bringing AI into medicine via a Parkinson's drug”
